08:58 AM EDT, 09/11/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) on Wednesday announced positive overall survival rate in its Phase 2 study of Bria-IMT with an immune check point inhibitor (CPI) in late stage metastatic breast cancer.

The most recent patients reported a median overall survival of 15.6 months (treated since 2022) compared with 6.7-9.3 months for similar patients reported in the literature. The latest data are also an improvement over BriaCell's 13.4 months median overall survival that was reported last December. These patients are being treated with the same Bria-IMT formulation being used in the company's ongoing Phase 3 pivotal study in metastatic breast cancer.

"We wanted to look at the Phase 2 data of those patients who most closely resemble the patients being treated in our ongoing phase 3 study and compare them to similar patients in the literature," said Chief Executive Dr. William V. Williams. "The nearly two-fold overall survival benefit we are seeing with the Bria-IMT regimen, together with the similar previously reported approximate doubling of progression free survival, compared with literature controls, strongly support our belief that Bria-IMT could have a meaningful impact in the lives of heavily pre-treated metastatic breast cancer patients."